Dr. Ruprecht Wiedemeyer is a 2012 Liz Tilberis Grantee. In this interview with OCRF's Sarah DeFeo, Dr. Wiedemeyer discusses his research and what it means to receive a grant from OCRF.
Dr. Kate Lawrenson is a 2012 Ann Schreiber Program of Excellence Grantee. In this interview with OCRF's Sarah DeFeo, Dr. Lawrenson discusses her research and what it means to receive a grant from OCRF.
Dr. Melinda Yates is a 2012 Ann Schreiber Program of Excellence Grantee. In this interview with OCRF's Sarah DeFeo, Dr. Yates discusses her research and what it means to receive a grant from OCRF.
Dr. Karen Cowden Dahl is a 2012 Liz Tilberis Grant Recipient. In this interview with OCRF's Sarah DeFeo, Dr. Cowden Dahl discusses her research and what it means to receive a grant from OCRF.
Dr. Selvendiran Karuppaiyah is a 2011 Liz Tilberis Grant Recipient. In this interview with OCRF's Sarah DeFeo, Dr. Karuppaiyah discusses his research and what it means to receive a grant from OCRF.
Dr. Joanna Burdette is a 2011 Liz Tilberis Grant Recipient. In this interview with OCRF's Sarah DeFeo, Dr. Burdette discusses her research and what it means to receive a grant from OCRF.
Dr. Tsz-Lun Yeung, Ph.D. is a 2011 Ann Schreiber Program of Excellence Grant Recipient.
Dr. Sarah Adams is a 2011 Liz Tilberis Grant Recipient.
Dr. Gregory Motz is a 2011 Ann Schreiber Program of Excellence Grantee. In this interview with OCRF's Sarah DeFeo, Dr. Motz discusses his research, what motivated him to focus his efforts on ovarian cancer research, and what it means to receive a grant from OCRF.
Dr. Ruth Perets is a 2011 Ann Schreiber Program of Excellence Grant Recipient. Her research is funded in part thanks to the support of The National Ovarian Cancer Coalition.
Dr. Jeff Boyd is Senior Vice President and Chief Scientific Officer of the Fox Chase Cancer Center in Philadelphia, PA. In November 2009 he was appointed Chair of OCRF's Scientific Advisory Committee. In this interview with OCRF's Sarah DeFeo, Dr. Boyd shares his thoughts on the most promising areas of ovarian cancer research, and how OCRF is uniquely positioned to make a real impact on the disease.
Dr. Mitchell Ho is a Principal Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute. He is a 2007 recipient of OCRF's Individual Investigator Award
Get email updates about research news, action alerts, and ways to join the fight.
